Bio-Techne Divests Exosome Diagnostics Business
Bio-Techne Corporation (NASDAQ: TECH) has announced a significant strategic move by agreeing to sell its Exosome Diagnostics Inc. business to Mdxhealth SA. This transfer includes key assets such as the ExoDx Prostate (EPI) test and a CLIA-certified clinical laboratory. Furthermore, Bio-Techne will maintain access to proprietary exosome technology to support ongoing diagnostic kit development, reinforcing its commitment to advancing precision diagnostics.
Strategic Benefits of the Transaction
President and CEO of Bio-Techne, Kim Kelderman, expressed confidence in Mdxhealth as the purchaser of the ExoDx Prostate test and related laboratory. According to Kelderman, Mdxhealth has made considerable strides in establishing itself as a leader in urology and prostate cancer diagnostics. By integrating the ExoDx Prostate test into their offerings, Mdxhealth is set to enhance its market leadership further.
This divestiture aligns with Bio-Techne's goal of streamlining its portfolio to focus on innovative, high-value products in the life sciences and clinical diagnostics sectors. It allows the company to allocate additional resources for the development of advanced products that meet the evolving needs of the healthcare industry.
Mdxhealth's Vision for Growth
Michael McGarrity, CEO of Mdxhealth, commented on the acquisition’s strategic fit with their expanding portfolio in urology and prostate cancer diagnostics. The ExoDx Prostate test empowers patients with critical information needed to make informed healthcare decisions. By minimizing unnecessary biopsies, the test has become an essential tool in patient care. Mdxhealth aims to build on Bio-Techne's success by further enhancing the utility of the ExoDx Prostate test for both patients and physicians.
Financial Aspects of the Agreement
The sale involves Bio-Techne receiving $5 million worth of Mdxhealth stock along with potential future considerations. The completion of this transaction is anticipated to occur by the end of the first quarter of Bio-Techne's fiscal 2026, marking a crucial step in the company’s evolving strategy within the life sciences sector.
Insights from Bio-Techne
Bio-Techne is scheduled to discuss this significant transaction along with its fourth-quarter fiscal performance during an upcoming earnings call. Stakeholders will be able to listen live and gain insights into how these organizational changes are poised to impact the company's trajectory moving forward.
Bio-Techne positions itself as a premier global life sciences company. With a strong portfolio comprising innovative tools and bioactive reagents tailored for the research and clinical diagnostic communities, Bio-Techne generated approximately $1.2 billion in net sales for the previous fiscal year while employing over 3,000 professionals worldwide.
Frequently Asked Questions
What does the divestiture of Exosome Diagnostics mean for Bio-Techne?
The divestiture allows Bio-Techne to focus on developing high-value products in precision diagnostics, enhancing its market position.
Who is acquiring Bio-Techne's Exosome Diagnostics business?
Mdxhealth SA is acquiring Bio-Techne's Exosome Diagnostics business, including the ExoDx Prostate test.
How will this sale benefit Mdxhealth?
This acquisition strengthens Mdxhealth's position in urology and prostate cancer diagnostics, providing important tools for patient care.
What are the financial expectations from this transaction?
Bio-Techne will receive $5 million in Mdxhealth stock, with additional future considerations expected.
When is Bio-Techne's earnings call discussing this change?
The earnings call is set for the day after the announcement, providing details on the transaction and fiscal performance.
